NEWSROOM

IMUN

Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients

Winter Park, FL., June 9, 2020, - Immune Therapeutics, Inc. (OTC PINK: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment of COVID-19. The submission has been reviewed by the COVID-19 Scientific/Technical Triage Team and has been assigned for review by the Division of Pulmonology, Allergy and Critical Care (DPACC), part of the Office of...

read more

Immune Therapeutics, Inc. Focusing to Drive Shareholder Value

Winter Park, FL, May 6, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive shareholder value. Recent economic events require that Immune revisit its business model and explore new opportunities to drive shareholder value. The Board of Directors is evaluating its...

read more

Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications

Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and Inflammatory Disease in Companion Animals Orlando Florida April 16, 2020 – Immune Therapeutics Inc. (OTC PINK: IMUN), a clinical-stage pharmaceutical company, and Forte Biotechnology Intl Corp, a privately-held...

read more

Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19. Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Drug Development Programs Also Moving Forward

ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease today announced the signing of a binding letter of intent to collaborate with Cytocom, Inc. (“Cytocom” or “CYTO”) for the development of Lodonal™ and IRT-101 for use...

read more

Immune Therapeutics, Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Immune Therapeutics, Inc. Files Amendment on 1000 to 1 Reverse and Name Change with the State of Florida Division of Corporations Awaiting Completion of FINRA Approval Process ORLANDO, Florida, March 9, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases and cancer today announced an update on the pending...

read more

Immune Therapeutics, Inc. Appoints New Independent Director

Fort Collins, Co., February 18, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced the appointment of Mr. Michael L. Sander to its Board of Directors who will succeed Jack Brewer who served on the Company’s Board of Directors since 2018 and Edward Teraskiewicz, who served on the Company’s Board of...

read more

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Awaiting completion of FINRA approval process ORLANDO, Fla., February 11, 2020 -- Immune Therapeutics, Inc. (OTC PINK: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics. Immune Therapeutics originally submitted the reverse and name request for...

read more

Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company

The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline   ORLANDO, Fla., December 16th, 2019  -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Aletheia in an all-stock transaction.  Pursuant to completion of a definitive agreement,...

read more

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

    ORLANDO, Fla., October 28, 2019 — – Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy  and a systems biology approach today announced that its Board of Directors and a majority of its shareholders have approved a reverse stock split of the Company’s issued and outstanding common shares at a ratio of 1,000 to 1 and a...

read more

Immune Therapeutics, Inc. Announces Advisory Board Appointments

  ORLANDO, Fla., October 22, 2019 -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics. ”Immune Therapeutics is fortunate to have an individual as capable as Dr. Buckheit helping...

read more

Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today

                Immune Therapeutics Inc. Management Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 26, 2019 – – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Immune...

read more

Immune Therapeutics Inc Advises All Shareholders to Vote Their Proxy Card Today

      Immune Therapeutics Inc Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 17, 2019) -- – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Over the last week...

read more

Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors

          ORLANDO, Fla., September 23, 2019 — –Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis is pleased to announce the appointment of Michael K. Handley as the new Chief Executive Officer of Immune Therapeutics’ and Member of the Board...

read more

Immune Therapeutics Revises and Resends Proxy Statement

             ORLANDO, FL – September 10, 2019 -- – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, has filed a Revised Definitive Proxy Statement (the “Revised Proxy Statement”) due to the discovery that, as a result of an error outside of the Company’s control, shareholders...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »